Publicaciones de Interés
Datos Pantumoral
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
N Engl J Med. 2018 FebDatos Pantumoral
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Lancet Oncol. 2020 AprDatos de Carcinoma de Tiroides
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Eur J Endocrinol. 2022 AprDatos de Cáncer de Pulmón
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers
JCO Precis Oncol 2022 JanDatos de Sarcomas
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Cancer. 2023 DecDatos de Tumores Pediátricos
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Lancet Oncol. 2018 MayDatos de Tumor del SNC
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro Oncol. 2022 Jun Datos de Cánceres de Glándulas Salivares
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Oncologist. 2022 MayDatos de Inhibidores TRK
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer
Am J Manag Care. 2022 Jan